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Abstract
Background: Despite the dramatic decline in the incidence of invasive pneumococcal disease (IPD) observed since the
introduction of conjugate vaccination, it is feared that several factors may undermine the future effectiveness of the
vaccines. In particular, pathogenic pneumococci may switch their capsular types and evade vaccine-conferred immunity.
Methodology/Principal Findings: Here, we first review the literature and summarize the available epidemiological data on
capsular switch for S. pneumoniae. We estimate the weekly probability that a persistently carried strain may switch its
capsule from four studies, totalling 516 children and 6 years of follow-up, at 1.5610
23/week [4.6610
25–4.8610
23/week].
There is not enough power to assess an increase in this frequency in vaccinated individuals. Then, we use a mathematical
model of pneumococcal transmission to quantify the impact of capsular switch on the incidence of IPD in a vaccinated
population. In this model, we investigate a wide range of values for the frequency of vaccine-selected capsular switch.
Predictions show that, with vaccine-independent switching only, IPD incidence in children should be down by 48% 5 years
after the introduction of the vaccine with high coverage. Introducing vaccine-selected capsular switch at a frequency up to
0.01/week shows little effect on this decrease; yearly, at most 3 excess cases of IPD per 10
6 children might occur due to
switched pneumococcal strains.
Conclusions: Based on all available data and model predictions, the existence of capsular switch by itself should not impact
significantly the efficacy of pneumococcal conjugate vaccination on IPD incidence. This optimistic result should be
tempered by the fact that the selective pressure induced by the vaccine is currently increasing along with vaccine coverage
worldwide; continued surveillance of pneumococcal populations remains of the utmost importance, in particular during
clinical trials of the new conjugate vaccines.
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Introduction
Pneumococcal disease is a major cause of mortality and
morbidity worldwide. In the United States alone, S. pneumoniae
was responsible for 3 000 cases of meningitis, 500 000 cases of
pneumonia, and 7 000 000 cases of otitis media each year before
the introduction of conjugate vaccination in 2000 [1].
A heptavalent pneumococcal conjugate vaccine has been
available for a few years. This vaccine covers the 7 most frequently
carried pneumococcal serotypes in the United States, which are
also among the most invasive serotypes. Since its introduction, a
marked decrease in the incidence of invasive pneumococcal
disease (IPD) has been reported [2]. Because of herd immunity,
this decrease is not restricted to vaccinated children and has been
observed in the entire population [2,3].
Nevertheless, several factors may undermine the efficacy of the
vaccine. Several studies have reported evidence of replacement of
vaccine serotypes by non-vaccine serotypes in vaccinated popu-
lations [4,5]. Mathematical models have suggested that this may in
the long term cancel the impact of vaccination on pneumococcal
colonization rates [6,7] and lessen its impact on IPD incidence [8].
Another worrying factor is the suspicion that some highly
invasive or antibiotic resistant pneumococci may have a propensity
to switch their capsular type, thereby evading vaccine-conferred
immunity [9–11]. Several studies have indeed reported the
emergence in vaccinated populations of new pneumococcal clones
expressing non-vaccine serotypes, but genetically closely related to
vaccine serotypes [9,11–14]. In particular, since the introduction
of conjugate vaccination, serotype 19A has emerged as the
predominant invasive pneumococcal serotype in the United States
[15]. Molecular epidemiology analyses suggest that this increase is
largely attributable to the expansion of capsular switch variants
[16]. However, evidence of capsular switch has also been reported
in S. pneumoniae before the vaccination era, and the influence of the
conjugate vaccine remains unclear [9,17,18]. Furthermore, little is
known on the actual frequency at which pneumococci may switch
their capsular type [18,19].
In this study, we first review 4 studies presenting longitudinal
data on pneumococcal carriage in the population to estimate the
frequency of ‘‘natural’’ vaccine-independent capsular switch. Since
it is suspected that conjugate vaccination may favour selection of
capsular switch in vaccine-covered or related serotypes [9,14], we
PLoS ONE | www.plosone.org 1 September 2008 | Volume 3 | Issue 9 | e3244specifically investigate this possibility from those of the studies
which also provide data on the vaccination status of individuals.
Secondly, we use the gathered information in a mathematical
model of pneumococcal transmission to quantify the possible
changes induced by capsular switch on the incidence of invasive
pneumococcal disease in vaccinated populations.
Methods
Review on pneumococcal capsular switch
In this article, we distinguish between ‘‘natural’’ capsular switch,
which is the propensity for a pneumococcal strain to switch its
capsular type independently of its environment, and vaccine-
selected capsular switch, which results from the selective pressure
of conjugate vaccination on pneumococcal strains. The vaccine-
selected capsular switch phenomenon is added to the natural
capsular switch phenomenon in vaccinated individuals.
Search strategy and selection criteria for the
review. Data for the review were identified by a systematic
search of Medline and references from relevant articles. Search
terms were ‘‘longitudinal’’ (or ‘‘birth’’, ‘‘scheduled’’, ‘‘month*’’,
‘‘week*’’, ‘‘age*’’), ‘‘surveillance’’ (or ‘‘cohort’’, ‘‘trial’’, ‘‘monitor*’’,
follow*’’), ‘‘colonization’’ (or ‘‘carriage’’), ‘‘isolate*’’ (or ‘‘sample*’’),
‘‘serotype*’’ (or ‘‘genetic*’’, ‘‘multilocus’’, ‘‘capsul*’’, ‘‘molecular’’)
and ‘‘pneumoniae’’ (or ‘‘pneumococc*’’).
English and French language papers were reviewed. We included
only those studies which provided detailed longitudinal data on
pneumococcal carriage in a population with information on
serotypes and MLST genotypes of carried isolates at all sampling
times, as well as reports on observed capsular switches. Conversely,
we excluded studies which did not provide detailed enough data.
Frequency of vaccine-independent ‘‘natural’’ capsular
switch. Capsular switch events were defined in all studies as
the consecutive isolation in persistently colonized individuals of
two isolates that were identified by MLST as closely related, but
that expressed different serotypes. The frequency of capsular
switch in a study was estimated as the ratio of the number of
observed switches by the total time during which switches may
have occurred.
In order to obtain the denominator, which represented the time
at risk for capsular switch, we computed the duration of observed
persistent pneumococcal colonization for all children included in
the study. For any given child, this was defined as the sum of all
durations between 2 consecutive positive samplings in the course
of the study. The time at risk was then calculated as the total
duration of persistent pneumococcal colonization, cumulated over
all children.
Investigation of vaccine-selected capsular switch. Vaccine-
selected capsular switch events were defined as the consecutive
isolation in persistently colonized vaccinated individuals of a vaccine
and a non-vaccine isolate (in that order) that were identified by
MLST as belonging to the same subtype. The frequency of vaccine-
selected capsular switch was defined as the weekly probability for a
vaccine-type strain colonizing a vaccinated individual to be selected
after it has switched its capsular type in order to evade vaccine-
conferred immunity.
Mathematical model of pneumococcal transmission in a
vaccinated population
We developed a mathematical model of pneumococcal
colonization in a partially vaccinated community (Figure 1). At
any given time, individuals reside in a compartment according to
their carrier status and to the characteristics of the pneumococcal
strain they may carry. The model depends on several parameters,
which are listed with their values in Table 1.
Capsular switch modeling. The model did not account for
all switching, but only for ‘‘excess’’ vaccine-selected capsular
switch, which may not be compensated. That is, we hypothesized
that conjugate vaccination aided the selection of switched variants
of the seven strains included in its formulation. The ‘‘natural’’
switch phenomenon, which affects all pneumococcal strains
regardless of vaccination, needs not be explicitly modeled as
switches to and from vaccine strains should compensate.
We investigated a frequency of vaccine-selected capsular switch
in vaccinated individuals ranging from 0 (no vaccine-selected
capsular switch) to 10
22/week.
Model structure. The model structure is depicted in Figure 1.
The seven serotypes covered by the heptavalent conjugate vaccine
(vaccine serotypes, namely serotypes 4, 6B, 9V, 14, 18C, 19F and
23F, representing 58% of all strains in Europe) are distinguished
fromotherserotypes(non-vaccineserotypes,representing42%ofall
strains). Non-vaccine serotypes deriving from the capsular
transformation of vaccine serotypes are further separated from
‘‘wild-type’’ non-vaccine serotypes. The vaccine is supposed to be
100% effective against colonization with vaccine serotypes.
Individuals in the model reside in one of 7 carriage states at any
given time: non carriers; carriers of vaccine serotypes (V); carriers
of non-vaccine serotypes deriving from the capsular switch of
vaccine serotypes (S); carriers of ‘‘wild-type’’ non-vaccine serotypes
(N); and multiple carriers who are colonized with two different
isolates (VS, VN and SN). Because the model also takes into
account the vaccination status, meaning that individuals can be
either vaccinated or not vaccinated, as well as two age classes
(,2 years old and .2 years old), there are 28 compartments in all.
Colonization modeling. Both the first acquisition of a
pneumococcal strain and the acquisition of a second strain
occurred following an infectious contact with a colonized
individual. The frequency of these infectious contacts depended on
the age and colonization status of the host, as well as on the strain
involved.
Observed colonization rates with vaccine and non-vaccine
serotypes in the pre-vaccine era suggest a reduced fitness in the
latter, which might be expressed by a lower transmissibility [20].
Here, we supposed a 0.98 ratio between the frequencies of infectious
contacts involving non-vaccine and vaccine serotypes. Switched
serotypes were supposed to have the samefitness as vaccine serotypes.
In order to model competition, the probability of acquisition of
a particular serotype was reduced by 50% in hosts already
carrying another serotype [7].
The frequencies of infectious contacts with vaccine strains in
uncolonized children and adults were calibrated to reflect
observed colonization rates in the pre-vaccine era (40% in
children under 2 years old [21], 20% for ‘‘adults’’ over 2 years
old [22]; 58% of vaccine serotypes).
The mean duration of colonization was supposed to be the same
for all types of strains in the model. The duration of pneumococcal
colonization was estimated from the literature at 13.8 weeks in
children ,2 years old, and at 4.4 weeks in adults [23].
Invasiveness modeling. We simplified our description by
assuming that all vaccine serotypes were invasive, whereas only a
portion of wild-type non-vaccine serotypes were. We also
hypothesized that capsular switch did not affect invasiveness,
implying that non-vaccine serotypes deriving from the capsular
transformation of vaccine serotypes remained invasive.
From colonization to invasive disease. Invasive
pneumococcal disease (IPD) incidence was presumed to occur in
a portion of incident colonization cases with invasive strains.
Switch and IPD Incidence
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invasiveness from longitudinal data on pneumococcal acquisition
and infection in children ,2 years old [23]. In this study,
serotype-specific attack rates were defined as the ratio of the
incidence of invasive pneumococcal disease to the incidence of
acquisition and were calculated to determine the expected number
of IPD cases for 100,000 acquisitions of each pneumococcal
serotype. We used these serotype-specific attack rates to compute
Table 1. Estimation of the switch frequency (weekly probability for a persistently carried pneumococcal strain to switch its
capsule).
Study
Number of reported
switches
Cumulated persistent carriage
duration (weeks, estimated) Estimated switch frequency (weeks
21)
(Barnes et al) [27] 1 121 8.2610
23
(Sluijter et al)
* [28] 1 169 5.9610
23
(Meats et al) [19] 0 3852 0
(Bogaert et al) [29] 3 3068 9.7610
24
Random effects pooled estimate from the 4 studies [30] 1.5610
23 [4.6610
25–4.8610
23]
*Regarding the second study [28], it is to be noted that although the article provided the results of all positive samplings in chronological order for all children, it did not
specify the corresponding sampling times. We therefore had to approximate the overall persistent colonization duration by supposing that all successive positive
samplings occurred consecutively at a 1 month interval.
doi:10.1371/journal.pone.0003244.t001
Figure 1. Model Structure within one age class. Individuals can be either uncolonized (U), colonized with vaccine serotypes (V), non-vaccine
serotypes resulting from the capsular switch of a vaccine serotype (S) or wild-type non-vaccine serotypes (N). Dual colonization is allowed (VS, VN or
SN). The model is structured into two age classes (children and adults). A portion of children are vaccinated, and vaccination immunity may last into
adulthood. Vaccinated individuals can only acquire colonization with non-vaccine-type pneumococci. Switch events may occur in vaccinated
individuals colonized with both vaccine and non-vaccine serotypes (VN) and are depicted by a bold arrow.
doi:10.1371/journal.pone.0003244.g001
Switch and IPD Incidence
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acquisitions), as well as the attack rate of invasive non-vaccine
serotypes (25 IPD cases/100,000 acquisitions) and the attack rate
of non-invasive non-vaccine serotypes (3.25 IPD cases/100,000
acquisitions) in children. For adults, it is thought that immuno-
logical history induces a reduction in attack rates [20,24]. We
calculated adult attack rates by dividing children attack rates by
4.5, in order to reproduce the difference between observed
incidences in children and adults in age-specific data on IPD [25].
We then determined the number of IPD cases/100,000 per
annum from model predictions by multiplying the number of
acquisitions of each strain type during a given year by the
corresponding mean attack rate in each age class.
Sensitivity analysis. In order to evaluate the robustness of
our results, we performed a sensitivity analysis of the model using
the Latin hypercube sampling-partial rank correlation coefficients
technique [26].
Results
Review on pneumococcal capsular switch
Selected studies (Table 2). Our systematic search of
Medline retrieved 147 original articles. Four epidemiological
studies providing data on capsular switch were found consistent
with our requirements [19,27–29].
The first study [19] aimed specifically at estimating the
frequency of serotype change. A birth cohort of a 100 infants
was followed for 2 years. There was no evidence for any change of
serotype due to capsular switch.
The second study [27] reported results from routine surveillance
in a day care centre over 7 years; one capsular switch event was
reported during an outbreak of colonization involving 14 children
between May 1990 and December 1991.
In the third study [28], 19 children were monitored during the
first 2 years of their life; one episode of capsular switch was
reported.
The fourth and most recent study [29] was a randomized
double-blind trial with the 7-valent conjugate pneumococcal
vaccine involving 383 children who were followed for 6 months; 3
episodes of capsular switch were reported.
Estimation of the ‘‘natural’’ vaccine-independent switch
frequency. Switch frequencies estimated from the 4 selected
studies are summarized in Table 1 and vary between 0 and
8.10
23/week. We also computed a random effects pooled estimate
of the switch frequency from all available data in the 4 studies,
which included a total of 5 reported switches for an overall
cumulated duration of persistent colonization of 5044 weeks
(DerSimonian and Laird meta-analysis [30]). The estimated
frequency was 1.5610
23/week (95% confidence interval,
[4.6610
25/week–4.8610
23/week]).
Investigation of vaccine-selected ‘‘excess’’ capsular
switch. Only one of the 4 selected studies provided data on
the vaccination status of colonized individuals [29]. Two more
studies of the impact of conjugate vaccination on pneumococcal
colonization were identified [31,32]; these 2 studies looked at
capsular switch but did not provide full individual data.
Neither of these studies provided any major evidence for an
increased frequency of strains with suspected capsular changes
among pneumococci isolated from the nasopharyngeal samples of
vaccinees. In the last identified study [32], possible capsular
switching from a non-vaccine serotype toward a vaccine serotype
was detected once among 197 isolates collected over 1 year in
vaccinated children.
As a whole, the available data was too scarce to allow any
conclusions to be drawn regarding the possibility of an increased
switch frequency due to the selective immunological pressure of
vaccination.
Mathematical model: validation and predictions
We simulated the introduction of the heptavalent conjugate
vaccine with 90% coverage, under various scenarios regarding the
actual frequency of vaccine-selected capsular switch in vaccinated
Table 2. Model parameters.
Parameter Estimated value Reference
Mean duration of pneumococcal colonization in children 13.8 weeks [23]
Mean duration of pneumococcal colonization in adults 4.4 weeks **
Rate of infectious contacts among children 0.4 weeks
21 **
Rate of infectious contacts between children and adults 0.25 weeks
21 **
Rate of infectious contacts among adults 0.26 weeks
21 **
Reduction of the acquisition probability in colonized individuals 50% **
Non-vaccine isolates transmissibility-vaccine isolates transmissibility ratio (fitness parameter) 0.98 [36]
Attack rates in children (IPD cases per 100,000 acquisitions) [23]
vaccine serotypes 13 IPD/100,000
nonvaccine serotypes 6.5 IPD/100,000
Attack rates in adults (IPD cases per 100,000 acquisitions) [23,25]
vaccine serotypes 3 IPD/100,000
nonvaccine serotypes 1.5 IPD/100,000
Mean duration of vaccine immunity after 2 years old 10 years [48]
Vaccine coverage 0–100%
Vaccine-selected capsular switch frequency 0–10
22 weeks
21
**Value resulting from a calibration of the model in order to reproduce observed age-specific data on pneumococcal colonisation.
doi:10.1371/journal.pone.0003244.t002
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pneumococcal population in the post-vaccine era, with a
frequency of vaccine-selected capsular switch fixed at 0
(Figure 2a), 10
24/week (Figure 2b) and 10
23/week (Figure 2c).
Figure 3 provides the yearly incidence of IPD in children 5 years
after the introduction of the vaccine for vaccine-selected capsular
switch frequencies between 0 and 10
22/week; the pre-vaccination
incidence is also presented as a reference.
‘‘Long-term’’ pneumococcal population. Following the
introduction of the vaccine, colonization with vaccine-type isolates
decreased while colonization with non-vaccine-type isolates
increased (Figure 2). Both the speed and the extent of this
Figure 2. Time changes in the pneumococcal population in the post-vaccine era: global colonization rate (bold line), colonization
with vaccine serotypes (dashed line), non-vaccine serotypes (dotted lines), and dual colonization with vaccine and non-vaccine
serotypes (full line), a) with a frequency of vaccine-selected capsular switch r=0, b) with a frequency of vaccine-selected capsular
switch r=10
24/week, and c) with a frequency of vaccine-selected capsular switch r=10
23/week.
doi:10.1371/journal.pone.0003244.g002
Switch and IPD Incidence
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capsular switch. For a 10
23/sem frequency of vaccine-selected
capsular switch, the overall prevalence of carriage in the
population had regained its pre-vaccine level after 10 years of
simulated vaccination (Figure 2c).
Switched strains constituted more than 30% of all invasive
strains for vaccine-selected capsular switch frequencies over 10
24/
week. However, non-invasive strains still represented at least half
of all pneumococcal strains, even for high selected switch
frequencies in vaccinated individuals (data not shown).
Simulations with a less extensive vaccination coverage led to
similar results provided the coverage remained over 40%.
Comparison of model predictions with observed
data. In most European countries, the reported incidence of
IPD in the pre-vaccination era was between 10 and 24 cases/
100,000 per annum among children [25,33]. This is consistent
with the 18.7 IPD cases/100,000 children predicted by the model
in the absence of vaccination (Figure 3).
After 5 years of vaccination, the predicted annual incidence was
reduced by more than 40% in children (Figure 3), and more than
30% in the general population (data not shown). This is consistent
with observed reductions in European vaccinated populations
[34,35].
Predictions on the impact of capsular switch. Without
any vaccination-selected switch, the expected IPD incidence was
reduced by 48% after 5 years of vaccination. For switch
frequencies up to 10
22/week, this reduction remained significant
at over 40% (Figure 3).
However, vaccine-selected switch in vaccinated individuals led
to excess IPD cases. Table 3 provides the expected number of
supplemental IPD cases in children, cumulated over the 10 years
following the introduction of conjugate vaccination. A high
vaccine-selected switch frequency (over 7,5.10
23/week) induced
3 excess IPD cases per 100,000 children over these 10 years.
Sensitivity analysis. The results of the sensitivity analysis are
given in Table 4. The most critical parameters for predicting the
incidence of IPD in the post-vaccine era were the duration of
colonization in adults and the rate of infectious contacts between
adults. Other important parameters were the rate of infectious
contacts between children and adults, as well as the attack rate of
non-vaccine serotypes.
Discussion
Combining literature review and mathematical modelling, we
investigated the potential impact of capsule switching on the
efficacy of conjugate pneumococcal vaccination. Although there
was not enough statistical power to quantify precisely the vaccine-
selected capsular switch frequency among vaccinated individuals,
Figure 3. Invasive Pneumococcal Disease (IPD) incidence in children ,2 years old (per 100,000 children, per year) 5 years after the
introduction of a conjugate vaccine, as a function of the frequency of capsular switch selected in vaccinated individuals, for a 90%
vaccination coverage. The origin of the cases (vaccine strains, non-vaccine strains, switched strains) is specified, and the expected incidence
without vaccination is also depicted as a reference.
doi:10.1371/journal.pone.0003244.g003
Table 3. IPD cases due to capsular switch. Number of IPD
cases due to switched pneumococcal strains, per 100,000
children under 2 years old, cumulated over the 10 years
following the introduction of conjugate vaccination, as a
function of the frequency of capsular switch selected in
vaccinated individuals.
Vaccine-selected switch
frequency (weeks
21)
Number of IPD cases (for 100,000
children) due to switched strains,
cumulated over 10 years
0–2610
24 0
3610
24–1.6610
23 1
1.7610
23–5.8610
23 2
5.9610
23–10
22 3
Vaccination coverage is fixed at 90%.
doi:10.1371/journal.pone.0003244.t003
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reduction in IPD incidence induced by the vaccine. This is in part
due to competition between switched isolates and other non-
vaccine isolates in vaccinated populations.
Discussion of the switch frequency estimation
Estimating the switch frequency from published studies only
should be challenged, as available data are scarce and exhibit
several limitations, such as being restricted to antibiotic-resistant
populations, specific age groups or invasive infections [18].
Because the data was so scarce, we could only estimate the
switch frequency with a wide confidence interval. Moreover, it is
possible that this frequency depends on the pneumococcal
serotype or on characteristics of the human host (such as age),
but we were unable to investigate this hypothesis.
Finally, it could be argued that there is no direct proof that the
serotype changes reported in the studies we selected are indeed
due to capsular switch, as many events can go unobserved between
two consecutive samplings. This is all the more true when
samplings occur many months apart. For instance, in the study by
Bogaert and colleagues [29], it is possible that the observed
consecutive colonization at a 6-month interval with different
serotype variants of closely related strains merely suggests the
recruitment of a second isolate with identical genotype. Converse-
ly, it is also possible that some capsular switch events may have
gone undetected in this study. It would be interesting to use a data
augmentation technique such as Markov Chain Monte Carlo on
the data from these studies in order to obtain more robust
estimates of the switch frequency [36].
Discussion of model hypotheses
Vaccine-independent capsular switch vs. vaccine-selected
capsular switch. We hypothesized that in the absence of vaccine
pressure, switches to and from vaccine strains should be balanced.
This allowed us not to take into account vaccine-independent
capsular switch in our model. Although it seems possible that the
underlying genetic nature of different switches may have specific
directionality, our balance hypothesis is supported by the fact that, in
a given location, the frequency distribution of particular
pneumococcal serotypes or serogroups in IPD has remained nearly
constant over several decades before conjugate vaccination [20].
In vaccinated individuals however, non-vaccine isolates which
result from the natural switch of a vaccine isolate may persist
under selective pressure due to vaccination, whereas vaccine
isolates will not. Therefore, we included the possibility for vaccine-
selected capsular switch in vaccinated individuals in our model.
Range of values for the vaccine-selected switch
frequency. The emergence of new clones expressing non-
vaccine serotypes has been observed in countries where the
vaccine was widely used [14]. However, although this raises
suspicions that conjugate vaccination might increase the frequency
of capsule switching from vaccine-covered types, quantification is
not yet possible from epidemiological data. Here, we supposed
that vaccination could not do much more than double the overall
‘‘natural’’ propensity of pneumococci to switch their capsule.
Based on our estimation of the frequency of natural capsular
switch between 5.10
25/week and 5.10
23/week, this led us to
investigate vaccine-selected switch frequencies in vaccinated
individuals between 0 and 10
22/week.
In order to be as conservative as possible, we also investigated
vaccine-selected switch frequencies up to 0.1/week, although we
chose not to present this data in this article. For such high
frequencies, we expect switched isolated to be responsible for
nearly half of IPD cases 5 years after the introduction of the
vaccine. However, because this increase in switched isolates should
for the most part occur as replacement of non-vaccine isolates,
rather than add to the overall colonization, the impact on IPD
incidence may remain limited. For instance, vaccine-selected
capsular switch should not lead to more than 5 excess IPD cases
per 100,000 children over the 10 years following the introduction
of conjugate vaccination.
Capsular type and pathogenicity. A major model
hypothesis is that capsular switch does not affect the
pathogenicity of a given pneumococcal strain, implying that a
highly virulent vaccine strain would still be as virulent if it switched
its capsular type to express a non-vaccine serotype. However, this
is a widely debated issue, as earlier studies have shown
complicated interactions between capsular type and other genes
in determining pneumococcal virulence.
The capsule has long been identified as a virulence factor by
virtue of its antiphagocytic activity, and acapsular mutants are
known to be avirulent [37]. Several molecular epidemiology
Table 4. Sensitivity analysis of the incidence of IPD 5 years after the introduction of conjugate vaccination. Vaccination coverage is
fixed at 90% and the frequency of vaccine-selected capsular switch is fixed at 10
23/week. Critical parameters are in bold.
Parameter PRCC
a
Mean duration of pneumococcal colonization in adults 0.925
Mean duration of pneumococcal colonization in children 0.223
Rate of infectious contacts among children 0.048
Rate of infectious contacts between children and adults 0.469
Rate of infectious contacts among adults 0.896
Reduction of the acquisition probability in colonized individuals 0.265
Non-vaccine isolates transmissibility-vaccine isolates transmissibility ratio (fitness parameter) 0.071
Attack rate of vaccine serotypes 0.134
Attack rate of non-vaccine serotypes 0.369
Mean duration of vaccine immunity after 2 years old 0.060
aPartial rank correlation coefficients (PRCC) indicate the degree of monotonicity between a specific input variable and a particular outcome variable. The sign of the
PRCC indicates the qualitative relationship between input and output variables. The magnitude indicates the importance of uncertainty in estimating the value of the
input variable in contributing to the imprecision in predicting the value of the outcome variable.
doi:10.1371/journal.pone.0003244.t004
Switch and IPD Incidence
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capsule and the ability of pneumococci to cause invasive disease
[38,39]. However, in two recent studies, isolates belonging to the
same clone but with different capsules because of serotype switch
were found to have the same disease potential [24,40].
According to several experimental studies based on the
construction of chimeric pneumococcal mutants with a switched
capsular type, the capsule type is not the only determinant of
pathogenicity [41,42]. Hence the virulence of a switched strain
may not be predictable from that of the virulence of the original
strain. Moreover, other genetic factors might be involved in
colonization and in non-invasive pneumococcal disease [43].
In this study, we aimed at evaluating the potential impact of
capsular switch on the long-term effectiveness of current
pneumococcal conjugate vaccines, based on the suspicion that
the constant usage of these vaccines may aid the expansion of
serotype switch variants. In that context, our hypothesis that
switched vaccine-type pneumococcal strains retained their higher
virulence despite expressing non-vaccine serotypes constituted a
worst-case scenario.
Multiple colonization and competition. Colonization
studies show that many people carry more than one
pneumococcal type at the same time, although multiple
colonization is less frequent than would be expected if each
serotype circulated independently of the others [44]. Because the
most probable mechanism for vaccine-selected capsular switching
involves multiple colonization of a vaccinated host, we allowed for
dual colonization in our model, but we also hypothesized that
there was some level of competition. We modelled competition by
a reduction in the probability of acquisition of a second strain in an
already colonized host [7]. Although interference between
pneumococcal strains is documented [45], there was little data
to estimate this competition parameter. Based on the sensitivity
analysis where we investigated reductions in acquisition
probability ranging from 25% to 75%, this parameter does not
appear to be the most critical for predicting IPD incidence in the
post-vaccine era.
Fitness. In the pre-vaccine era, the portion of pneumococcal
colonization attributable to vaccine serotypes seems to have
remained stable over time at a level .50% in various parts of the
world, although it varied geographically. In a context of multiple
colonization, this strongly suggests that vaccine serotypes have an
increased fitness for colonization. This fitness may be expressed
either as increased carriage duration or as higher transmissibility.
However, in an earlier study based on longitudinal data, we found
little to no differences in the mean duration of carriage and
transmission rates of vaccine serotypes and nonvaccine serotypes
groups [36]. Here, we included in the model a slightly reduced
transmissibility for non-vaccine serotypes; even with identical
carriage durations, this allowed us to reproduce the observed
differences in prevalence before the introduction of the vaccine.
Discussion of model predictions
Because we evaluated the invasive attack rates of pneumococci
from European data [23], we used European data on IPD
incidence to validate model predictions. This incidence is
significantly inferior to that reported in the United States, as a 4
to 7-fold difference has been reported between the United States
and Europe in the pre-vaccination era [25,33]. This may arise
from different medical practices between countries, such as
admission thresholds and blood culture rates [25]. Model
parameters could easily be adjusted to reflect US IPD incidence,
provided data on serotype-specific attack rates in the US became
available.
According to our predictions, the reduction in IPD incidence
after 5 years of vaccination should only be around 40–50% in
children, whereas observations in the United States showed a 69%
reduction in children under 2 years old after 3 years of vaccination
[2]. Reasons for this apparent discrepancy are twofold. First,
again, we focused on the European rather than US context; this
means that the initial serotype coverage of the heptavalent vaccine
was noticeably less favourable (58% of carried serotypes instead of
approximately 80%). Second, as evidenced in previous work [6],
our model predicts the replacement of vaccine serotypes by non-
vaccine serotypes. Despite differing attack rates, this should be
expected to lessen the impact of vaccination on IPD incidence
within a five-year timeframe [8]. Recent data showing a re-
increase in non-vaccine IPD incidence in the US support these
predictions [5,46,47].
Conclusions
Despite the significant short-term impact of conjugate pneu-
mococcal vaccination reported in the US, it has been predicted
from mathematical models that non-vaccine serotypes may come
to replace vaccine serotypes, with implications for the long-term
effectiveness of the vaccines. This is supported by recent data from
various countries [47]. However, suspicions that pneumococci
expressing vaccine serotypes may be incited to switch their
capsule, thereby evading vaccine immunity while retaining their
invasiveness and their high levels of antibiotic resistance, may be
even more worrying [12]. Indeed, this could lead to a re-increase
in highly resistant IPD in vaccinated populations.
The new conjugate vaccines with increased valence which
should be available in years to come might–at least in the short
term-help lessen the extent and speed of serotype replacement [6].
On the other hand, the potential impact of vaccine-selected
capsular switch could only increase with the number of serotypes
covered by the vaccine.
Here, we show that, based on the limited data available, the
extent of this phenomenon should remain quite limited. This is in
agreement with recent data from the US [32]. Nevertheless, this
study stresses the major importance of collecting surveillance data
in vaccinated populations which will allow for the detection of any
switch event from vaccine to non-vaccine serotypes, as well as for
the quantification of the frequency of these events. This should
also be kept in mind when designing and analysing clinical trials
for new pneumococcal vaccines with higher valence.
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